Detailed Narrative
Strong Financial Performance in Q4 and FY26
Lupin reported its 15th consecutive quarter of year-over-year growth, with Q4 FY26 total revenue from operations reaching INR 7,475 crores, a 32% YoY increase. Full-year FY26 revenue stood at INR 27,958 crores, up 23% YoY. EBITDA for Q4 FY26 was INR 2,171 crores, growing 68% YoY, and the full-year EBITDA reached INR 8,160 crores, a 55% YoY increase, with margins expanding by 590 basis points to 29.7%, surpassing the guidance of 27-28%.
Robust US Business Growth Driven by New Products
The US business was a standout, achieving USD 1.3 billion in sales for FY26, an impressive 40% YoY growth. This was primarily driven by new product launches such as Tolvaptan, Mirabegron, and complex injectables like Risperdal Consta® with CGT Exclusivity. The company plans to launch over 50 products in the US over the next three years, including 10 exclusive first-to-files, 4 biosimilars, and 2-3 505(b)(2)s, aiming to sustain its billion-dollar-plus revenue in FY27 despite anticipated competition.
India Business Outperforms IPM with Strategic Focus
India's business grew 11.5% YoY in Q4 FY26, with the core prescription segment expanding 14.5%, outperforming the Indian Pharmaceutical Market (IPM) growth by 1.3 times. For the full year, prescription growth was 10.6% against IPM's 9.9%. The chronic segment now constitutes 66% of the portfolio, with a target to reach 70% in the next five years, supported by strong performance in respiratory and cardiac segments.
Expansion in Emerging and Other Developed Markets
Emerging Markets delivered an impressive 49% YoY growth in Q4 FY26, led by Brazil, South Africa, and the Philippines, with Brazil growing 113% YoY in local currency due to Dapagliflozin. Other Developed Markets (Europe, Canada, Australia) grew 13.3% YoY in FY26, with European sales exceeding USD 200 million. The acquisition of VISUfarma is expected to further boost presence in Europe and specialty ophthalmology, with a target to cross USD 100 million in top-line contribution within 2-3 years.
Strategic R&D and Pipeline Development
R&D spend for FY26 was 7.5% of sales, with a continued focus on complex and specialty platforms, and is expected to be around 8% in FY27. The pipeline includes over 50 active products, with near-term emphasis on respiratory, complex injectables, and biosimilars. The company also highlighted a strong 505(b)(2) pipeline, with product launches anticipated in the next two years, and is strengthening its India Innovation portfolio through both in-house development and in-licensing.
EBITDA Margin Outlook and Cost Headwinds
While full-year EBITDA margin was 29.7%, Q4 saw a sequential decline attributed to increased manpower costs, a settlement payment to Astellas for Mirabegron, and foreign exchange impacts. The company has guided for an FY27 EBITDA margin of around 25%, factoring in anticipated competition for Tolvaptan and Mirabegron, as well as increased R&D expenditure. Inflationary pressures, including 15% higher ocean freight and 60% higher air freight, are also being managed and factored into the guidance.
Improved Net Cash Position and Capital Allocation Strategy
Lupin's net cash position significantly improved to INR 4,636 crores as of March 31, 2026, compared to INR 310 crores last year. The company emphasized a focus on strategic capital allocation towards specialty assets in Developed Markets, such as the VISUfarma acquisition, and assets that complement or bolster therapy areas in India. This approach aims to deploy capital effectively for long-term growth and mission fulfillment.